Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form

Rubegni, Pietro; Feci, Luca; Poggiali, S; Marotta, Giuseppe; D'Ascenzo, G; Murdaca, Francesco; Fimiani, Michele

doi:10.1111/bjd.12332

Cited by 6 publications

(1 citation statement)

References 17 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the mechanism is not well understood, ECP has clearly demonstrated therapeutic efficacy in refractory acute and cGVHD. [8][9][10][11] ECP allows tapering of immunosuppressive therapy and it can be effective in steroid-resistant GVHD. [12][13][14][15] However, the ECP procedure is expensive and requires a significant time commitment from the patient and the clinical staff.…”

Section: Introductionmentioning

confidence: 99%

Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization

Yerrabothala

Talebian²,

Klinker

et al. 2017

J of Clinical Apheresis

View full text Add to dashboard Cite

Extracorporeal photopheresis (ECP) is an established therapy for the treatment of graft-versus-host-disease (GVHD) following an allogeneic stem cell transplant. We performed a prospective analysis of patients receiving ECP treatment for GVHD to identify a clinical pathway and resource utilization of this process. The cohort included consecutive allogeneic stem cell recipients with GVHD. ECP was performed using the CELLEX Photopheresis System or the UVAR XTS Photopheresis System (Therakos, Inc, Exton, PA). A clinical pathway was developed and a time and motion study was conducted to define the resource utilization and costs associated with ECP. Patients were treated with either CELLEX (n = 18 procedures) or UVAR (n = 4 procedures). Total time commitment for each procedure for the 2 machines differed. The time for ECP was 117 min (median, range: 91-164 min) using CELLEX and 161 min (median; range: 140-210) using the UVAR-XTS machine. Total costs of each ECP procedure were $3420.50. There is a considerable time commitment of the patient and the clinical staff when employing ECP to treat GVHD. ECP costs are significant considering this is a prolonged therapy continued for several months. With this finalized pathway and costs, we have a standardized clinical pathway for the treatment of GVHD. We are addressing minimizing resource utilization while emphasizing quality care for these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization

Yerrabothala

Talebian²,

Klinker

et al. 2017

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experience

Batgi

Dal

Erkurt

et al. 2021

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Chronic lung allograft dysfunction

Vos

Verleden²,

Verleden³

2015

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

The recent introduction of CLAD importantly changed the clinical practice in lung transplant recipients. Given the relative low accuracy of the current diagnostic tools, future research should focus on specific biomarkers, more sensitive pulmonary function parameters and imaging techniques for timely CLAD diagnosis and phenotyping. Personalized or targeted therapeutic options for adequate prevention and treatment of CLAD are required.

show abstract

Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form

Abstract: ECP is effective in patients with mild to moderate steroid-refractory aGVHD (grade II-III). On the other hand, ECP did not prevent the development of cGVHD in our patients.

Cited by 6 publications

References 17 publications

Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization

Extracorporeal photopheresis for graft versus host disease: Identifying a clinical pathway and associated resource utilization

Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: A multicenter experience

Chronic lung allograft dysfunction

Contact Info

Product

Resources

About